Screening 12 items

Studies

Machine learning finds 26-253% more elevated-Lp(a) cases per test than universal screening, model of 438,579 (Eur J Prev Cardiol 2026)Eur J Prev Cardiol · March 2026 8
Korean Lp(a) task force proposes a 3-tier classification (30/50 mg/dL) tailored to Korean cohorts, position paper (J Lipid Atheroscler 2026)J Lipid Atheroscler · December 2025 8
Adding Lp(a) nearly doubles lipid-lowering-treatment eligibility in a 24,994-person primary-prevention cohort, SCAPIS (Atherosclerosis 2026)Atherosclerosis · June 2026 7
Lp(a) testing is available but underused in Argentina, national survey of 518 laboratories and 18,159 test results (J Clin Lipidol 2026)J Clin Lipidol · July 2026 6
Lp(a) of 149 nmol/L or more flags greater anatomic coronary disease burden, angiography registry of 2230 (Cardiovasc Revasc Med 2026)Cardiovasc Revasc Med · June 2026 6
Queensland Lp(a) testing rose from 652 to 4,364 tests a year over a decade, still underused (Heart Lung Circ 2026)Heart Lung Circ · April 2026 6
Patients find Lp(a) testing acceptable and motivating despite no approved therapy, INTERASPIRE survey across seven countries (Eur J Cardiovasc Nurs 2026)Eur J Cardiovasc Nurs · April 2026 6
Machine learning cuts number needed to test by more than 50% for finding elevated Lp(a), review of the ARISE framework (Curr Opin Lipidol 2026)Curr Opin Lipidol · January 2026 6
New point-of-care device shows strong correlation with lab Lp(a) assays, validation study of 58 samples (Clin Chem Lab Med 2026)Clin Chem Lab Med · January 2026 6
Lp(a) testing rose from 3,052 to 8,425 orders a year across a US health system, cohort of 450,412 (Am J Prev Cardiol 2026)Am J Prev Cardiol · December 2025 6
Quality-improvement initiative roughly doubles Lp(a) ordering in an outpatient cardiology clinic (J Clin Lipidol 2026)J Clin Lipidol · January 2026 5
Cost, distress and clinician reluctance are the main barriers to Lp(a) testing, qualitative study of 50 participants (J Clin Lipidol 2026)J Clin Lipidol · December 2025 5